Komal Gupte-Singh

453 total citations
35 papers, 316 citations indexed

About

Komal Gupte-Singh is a scholar working on Oncology, Molecular Biology and Economics and Econometrics. According to data from OpenAlex, Komal Gupte-Singh has authored 35 papers receiving a total of 316 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 7 papers in Molecular Biology and 6 papers in Economics and Econometrics. Recurrent topics in Komal Gupte-Singh's work include Cancer Immunotherapy and Biomarkers (12 papers), CAR-T cell therapy research (9 papers) and Melanoma and MAPK Pathways (6 papers). Komal Gupte-Singh is often cited by papers focused on Cancer Immunotherapy and Biomarkers (12 papers), CAR-T cell therapy research (9 papers) and Melanoma and MAPK Pathways (6 papers). Komal Gupte-Singh collaborates with scholars based in United States, United Kingdom and Sweden. Komal Gupte-Singh's co-authors include Kenneth A. Lawson, Sumati Rao, Ahmad A. Tarhini, Michael B. Atkins, David F. McDermott, Corey Ritchings, Meredith M. Regan, Lillian Werner, James Larkin and Harriet M. Kluger and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Cancer Research.

In The Last Decade

Komal Gupte-Singh

34 papers receiving 312 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Komal Gupte-Singh United States 9 150 72 62 48 43 35 316
Liqiang Guo China 9 81 0.5× 67 0.9× 55 0.9× 20 0.4× 9 0.2× 21 329
Mufiza Farid‐Kapadia Canada 7 95 0.6× 38 0.5× 14 0.2× 49 1.0× 16 0.4× 11 226
Kathleen Klein United States 12 50 0.3× 125 1.7× 14 0.2× 36 0.8× 37 0.9× 31 349
Samantha Cohen United States 9 101 0.7× 113 1.6× 14 0.2× 18 0.4× 17 0.4× 21 328
Raymond Lord United States 5 145 1.0× 28 0.4× 19 0.3× 95 2.0× 8 0.2× 8 265
Valerie Shiwen Yang Singapore 9 103 0.7× 94 1.3× 12 0.2× 29 0.6× 9 0.2× 29 266
Dezong Gao China 12 248 1.7× 75 1.0× 14 0.2× 57 1.2× 6 0.1× 19 450
Heather Symecko United States 10 113 0.8× 67 0.9× 12 0.2× 35 0.7× 10 0.2× 25 305
Michael Haboubi Canada 2 121 0.8× 43 0.6× 29 0.5× 21 0.4× 56 1.3× 3 501
Jonathan Hosey United States 3 121 0.8× 43 0.6× 28 0.5× 20 0.4× 56 1.3× 5 505

Countries citing papers authored by Komal Gupte-Singh

Since Specialization
Citations

This map shows the geographic impact of Komal Gupte-Singh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Komal Gupte-Singh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Komal Gupte-Singh more than expected).

Fields of papers citing papers by Komal Gupte-Singh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Komal Gupte-Singh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Komal Gupte-Singh. The network helps show where Komal Gupte-Singh may publish in the future.

Co-authorship network of co-authors of Komal Gupte-Singh

This figure shows the co-authorship network connecting the top 25 collaborators of Komal Gupte-Singh. A scholar is included among the top collaborators of Komal Gupte-Singh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Komal Gupte-Singh. Komal Gupte-Singh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lee, Scott D., Keith A. Betts, Ella X. Du, et al.. (2024). Real-World Patterns and Economic Burden Associated With Treatment Failure With Advanced Therapies in Patients With Moderate-to-Severe Ulcerative Colitis. Crohn s & Colitis 360. 6(2). otae026–otae026. 1 indexed citations
2.
3.
Swallow, Elyse, Oscar Patterson‐Lomba, Lei Yin, et al.. (2023). Comparative efficacy and safety of ozanimod and ponesimod for relapsing multiple sclerosis: A matching-adjusted indirect comparison. Multiple Sclerosis and Related Disorders. 71. 104551–104551. 7 indexed citations
4.
5.
Tornatore, Carlo, et al.. (2022). Identification of cognitive impairment, depression, and fatigue among multiple sclerosis patients in a large comprehensive care center: A mixed-methods, qualitative study. Multiple Sclerosis and Related Disorders. 68. 104117–104117. 6 indexed citations
6.
Dubinsky, Marla C., et al.. (2021). S694 Comparative Efficacy and Safety of Ozanimod vs Adalimumab and Vedolizumab in Patients with Moderately to Severely Active Ulcerative Colitis. The American Journal of Gastroenterology. 116(1). S314–S314. 6 indexed citations
7.
Stenehjem, David D., Solomon J. Lubinga, Komal Gupte-Singh, et al.. (2020). Real-World Effectiveness of Nivolumab Monotherapy After Prior Systemic Therapy in Advanced Non–Small-Cell Lung Cancer in the United States. Clinical Lung Cancer. 22(1). e35–e47. 5 indexed citations
8.
Tarhini, Ahmad A., et al.. (2019). Treatment patterns and outcomes for patients with unresectable stage III and metastatic melanoma in the USA. Journal of Comparative Effectiveness Research. 8(7). 461–473. 14 indexed citations
9.
Nadler, Eric, Janet L. Espirito, Thomas W. Wilson, et al.. (2019). Outcomes of nivolumab (NIVO)-treated patients (pts) with advanced non-small cell lung cancer (aNSCLC) in United States community oncology practice.. Journal of Clinical Oncology. 37(8_suppl). 119–119. 1 indexed citations
10.
Freeman, Morganna, Keith A. Betts, Shan Jiang, et al.. (2019). Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial Data. Advances in Therapy. 36(10). 2783–2796. 6 indexed citations
11.
Freeman, Morganna, Alexander N. Shoushtari, Keith A. Betts, et al.. (2018). Assessing the value of nivolumab (NIVO) versus placebo (PBO) and ipilimumab (IPI) as adjuvant therapy for resected melanoma.. Journal of Clinical Oncology. 36(15_suppl). 9594–9594. 2 indexed citations
12.
13.
Gupte-Singh, Komal, James P. Wilson, Jamie C. Barner, et al.. (2018). Patterns of antiepileptic drug use in patients with potential refractory epilepsy in Texas Medicaid. Epilepsy & Behavior. 87. 108–116. 8 indexed citations
14.
Tarhini, Ahmad A., David F. McDermott, Komal Gupte-Singh, et al.. (2018). Clinical and economic outcomes associated with sequential treatment in BRAF mutant advanced melanoma patients.. Journal of Clinical Oncology. 36(15_suppl). 9538–9538. 2 indexed citations
15.
16.
17.
Gupte-Singh, Komal, et al.. (2017). Economic Burden of Attention-Deficit/Hyperactivity Disorder among Pediatric Patients in the United States. Value in Health. 20(4). 602–609. 63 indexed citations
18.
19.
Gupte-Singh, Komal, et al.. (2016). Treatment Patterns Of Antiepileptic Drugs In Patients With Potential Refractory Epilepsy In The Texas Medicaid Program. Value in Health. 19(3). A71–A71. 1 indexed citations
20.
Gupte-Singh, Komal, Gilwan Kim, & Jamie C. Barner. (2015). Impact of comorbid depression on medication adherence and asthma-related healthcare costs in Texas Medicaid patients with asthma. Journal of Pharmaceutical Health Services Research. 6(4). 197–205. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Liqiang Guo Breakdown of academic impact, for papers by Mufiza Farid‐Kapadia Breakdown of academic impact, for papers by Kathleen Klein Breakdown of academic impact, for papers by Samantha Cohen Breakdown of academic impact, for papers by Raymond Lord Breakdown of academic impact, for papers by Valerie Shiwen Yang Breakdown of academic impact, for papers by Dezong Gao Breakdown of academic impact, for papers by Heather Symecko Breakdown of academic impact, for papers by Michael Haboubi Breakdown of academic impact, for papers by Jonathan Hosey
Rankless by CCL
2026